May 7, 2026 7:00 am EDT Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 4, 2026 4:30 pm EDT Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Apr 10, 2026 6:59 am EDT Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Apr 6, 2026 7:00 am EDT Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Mar 24, 2026 7:00 am EDT Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Mar 10, 2026 7:00 am EDT Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Feb 27, 2026 10:10 am EST Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Feb 25, 2026 6:59 am EST Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia